Across TCGA pan-cancer cohorts, IGHG2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGHG2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGHG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHG2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
DLBC, LIHC, and LGG are the cancer types where IGHG2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.